Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02351180 · ClinicalTrials.gov registry record · Phase 1
Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02351180 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 16 participants.
The verdict
NCT02351180, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the use of inhaled beclomethasone after a community-acquired respiratory viral infection in a lung transplant recipient decreases the risk of the subsequent development of chronic lung allograft dysfunction.
Interventions
- DRUG Placebo
- DRUG Inhaled beclomethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2021-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02351180
The ClinicalTrials.gov registry entry for NCT02351180 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02351180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02351180 about?
NCT02351180 is a clinical study titled "Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients". The purpose of this study is to determine if the use of inhaled beclomethasone after a community-acquired respiratory viral infection in a lung transplant recipient decreases the risk of the subsequent development of chronic lung allograft dysfunction.
What is the current status of trial NCT02351180?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2017-02-01. Estimated completion is 2021-01-31.
What interventions are being tested in trial NCT02351180?
The interventions under investigation include: Placebo (DRUG), Inhaled beclomethasone (DRUG).
Who is sponsoring clinical trial NCT02351180?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.